Intuitive Surgical (ISRG) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 17, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Mark Brosius, Evp & Chief Mfg And Supply Cha sold 46 shares at $444.38 ($20K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All ISRG insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
ISRG insider transactions (Form 4)
Open-market purchases and sales. 170 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 46411 held (−10%) | $444.38 | $20K | -8.0% | — |
| Nov 18SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 46365 held (−11%) | $437.33 | $20K | -6.5% | — |
| Nov 18SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 46319 held (−13%) | $430.63 | $20K | -5.0% | — |
| Nov 12SEC | Gary LoebGeneral Counsel | Sell Plan | 4006,236 held (−6%) | $458.15 | $183K | -10.7% | — |
| Nov 5SEC | Gary S. GuthartDirector | Sell Plan | 10,0001,194,530 held (−1%) | $457.34 | $4.6M | -10.6% | — |
| Nov 5SEC | Craig H. BarrattDirector | Sell Plan | 1,150 | $460.00 | $529K | -11.1% | — |
| Nov 2SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 5,4481,026 held (−84%) | $436.06 | $2.4M | -6.2% | — |
| Nov 2SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 63457 held (−12%) | $453.60 | $29K | -9.8% | — |
| Nov 2SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 61520 held (−10%) | $447.85 | $27K | -8.7% | — |
| Oct 28SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 61703 held (−8%) | $451.75 | $28K | -9.5% | — |
| Oct 28SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 61642 held (−9%) | $451.63 | $28K | -9.4% | — |
| Oct 28SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 61581 held (−10%) | $441.60 | $27K | -7.4% | — |
| Oct 26SEC | Gary S. GuthartDirector | Sell Plan | 20,0951,204,530 held (−2%) | $451.61 | $9.1M | -9.4% | — |
| Oct 26SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 4,0471,026 held (−80%) | $453.21 | $1.8M | -9.8% | — |
| Oct 26SEC | Craig H. BarrattDirector | Sell Plan | 1,150 | $443.80 | $510K | -7.8% | — |
| Oct 26SEC | Patricia L. WadorsSvp Chief Human Resources Offi | Sell Plan | 1,078 | $443.80 | $478K | -7.8% | — |
| Sep 16SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 5461,026 held (−35%) | $374.44 | $204K | +9.2% | — |
| Sep 16SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 5431,026 held (−35%) | $374.44 | $203K | +9.2% | — |
| Sep 11SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 25764 held (−3%) | $365.79 | $9K | +11.8% | — |
| Sep 11SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 23789 held (−3%) | $347.66 | $8K | +17.6% | — |
| Sep 9SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 46835 held (−5%) | $361.23 | $17K | +13.2% | — |
| Sep 9SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 23812 held (−3%) | $350.20 | $8K | +16.8% | — |
| Aug 21SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 77958 held (−7%) | $396.37 | $31K | +3.2% | — |
| Aug 21SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 77881 held (−8%) | $375.57 | $29K | +8.9% | — |
| Aug 19SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 771,035 held (−7%) | $394.26 | $30K | +3.7% | — |
| Aug 19SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 771,112 held (−6%) | $394.00 | $30K | +3.8% | — |
| Aug 19SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 771,189 held (−6%) | $390.67 | $30K | +4.7% | — |
| Aug 12SEC | Gary S. GuthartDirector | Sell Plan | 10,0001,245,679 held (−1%) | $400.00 | $4.0M | +2.2% | — |
| Aug 11SEC | Amy L. LaddDirector | Sell Plan | 400251 held (−61%) | $379.00 | $152K | +7.9% | — |
| Aug 11SEC | Amy L. LaddDirector | Sell Plan | 72179 held (−29%) | $393.10 | $28K | +4.0% | — |
| Aug 10SEC | Gary LoebGeneral Counsel | Sell Plan | 4005,320 held (−7%) | $379.00 | $152K | +7.9% | — |
| Jul 31SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 281,266 held (−2%) | $351.00 | $10K | +16.5% | — |
| Jul 31SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 281,294 held (−2%) | $346.83 | $10K | +17.9% | — |
| Jul 29SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 281,350 held (−2%) | $365.58 | $10K | +11.9% | — |
| Jul 29SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 281,322 held (−2%) | $360.21 | $10K | +13.5% | — |
| Jul 29SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 281,378 held (−2%) | $344.00 | $10K | +18.9% | — |
| Jun 12SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 251,406 held (−2%) | $414.13 | $10K | -1.2% | — |
| Jun 12SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 231,431 held (−2%) | $412.16 | $9K | -0.8% | — |
| Jun 10SEC | Gary LoebGeneral Counsel | Sell Plan | 4005,720 held (−7%) | $424.14 | $170K | -3.6% | — |
| Jun 10SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 231,454 held (−2%) | $424.14 | $10K | -3.6% | — |
| Jun 10SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 231,477 held (−2%) | $421.13 | $10K | -2.9% | — |
| Jun 10SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 231,500 held (−2%) | $420.12 | $10K | -2.6% | — |
| Jun 2SEC | Iman JeddiSvp & Gm Da Vinci Platforms & | Sell Plan | 5,6256,463 held (−47%) | $420.55 | $2.4M | -2.7% | — |
| May 22SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 181,541 held (−1%) | $446.04 | $8K | -8.3% | — |
| May 22SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 181,523 held (−1%) | $439.80 | $8K | -7.0% | — |
| May 20SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 181,577 held (−1%) | $440.70 | $8K | -7.2% | — |
| May 20SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 181,559 held (−1%) | $440.38 | $8K | -7.1% | — |
| May 20SEC | Mark BrosiusEvp & Chief Mfg And Supply Cha | Sell Plan | 181,595 held (−1%) | $422.47 | $8K | -3.2% | — |
| May 11SEC | Gary LoebGeneral Counsel | Sell Plan | 4006,120 held (−6%) | $446.95 | $179K | -8.5% | — |
| Apr 29SEC | Amy L. LaddDirector | Sell Plan | 500239 held (−68%) | $473.46 | $237K | -13.6% | — |
| Apr 29SEC | Amy L. LaddDirector | Sell Plan | 119120 held (−50%) | $463.50 | $55K | -11.8% | — |
| Mar 11SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 105 | $493.95 | $52K | -17.2% | — |
| Mar 10SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 6482,258 held (−22%) | $490.19 | $318K | -16.6% | — |
| Mar 10SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 6451,613 held (−29%) | $485.01 | $313K | -15.7% | — |
| Mar 5SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 2,3623,554 held (−40%) | $498.68 | $1.2M | -18.0% | — |
| Mar 5SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 6482,906 held (−18%) | $495.20 | $321K | -17.4% | — |
| Mar 5SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 6485,916 held (−10%) | $488.10 | $316K | -16.2% | — |
| Mar 3SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 4,728409 held (−92%) | $487.18 | $2.3M | -16.0% | — |
| Mar 3SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 249909 held (−22%) | $499.71 | $124K | -18.2% | — |
| Mar 3SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 1255,137 held (−2%) | $492.59 | $62K | -17.0% | — |
| Mar 3SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 1181,026 held (−10%) | $487.18 | $57K | -16.0% | — |
| Mar 2SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 2,345409 held (−85%) | $499.71 | $1.2M | -18.2% | — |
| Feb 27SEC | Patricia L. WadorsSvp Chief Human Resources Offi | Sell Plan | 220 | $499.71 | $110K | -18.2% | — |
| Feb 11SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 421409 held (−51%) | $494.96 | $208K | -17.4% | — |
| Feb 11SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 133660 held (−17%) | $494.96 | $66K | -17.4% | — |
| Feb 11SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 105830 held (−11%) | $494.65 | $52K | -17.3% | — |
| Jan 30SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 126 | $520.02 | $66K | -21.3% | — |
| Jan 28SEC | Gary S. GuthartDirector | Sell Plan | 24,5003,694 held (−87%) | $530.10 | $13.0M | -22.8% | — |
| Jan 28SEC | Gary S. GuthartDirector | Sell Plan | 1,40015,720 held (−8%) | $531.53 | $744K | -23.1% | — |
| Jan 28SEC | Gary S. GuthartDirector | Sell Plan | 1,40015,720 held (−8%) | $531.52 | $744K | -23.1% | — |
| Jan 28SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 125 | $532.61 | $67K | -23.2% | — |
| Jan 28SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 105 | $532.61 | $56K | -23.2% | — |
| Dec 17SEC | Mark BrosiusSee Remarks | Sell Plan | 464131 held (−78%) | $548.49 | $254K | -25.4% | — |
| Dec 17SEC | Mark BrosiusSee Remarks | Sell Plan | 312595 held (−34%) | $547.36 | $171K | -25.3% | — |
| Dec 15SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 4,500907 held (−83%) | $547.36 | $2.5M | -25.3% | — |
| Dec 15SEC | Mark BrosiusSvp & Chief Mfg And Supply Cha | Sell Plan | 464443 held (−51%) | $548.49 | $254K | -25.4% | — |
| Dec 10SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 104 | $559.90 | $58K | -27.0% | — |
| Dec 2SEC | Gary S. GuthartChair | Sell Plan | 22,8062,694 held (−89%) | $570.89 | $13.0M | -28.4% | — |
| Dec 2SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 125 | $568.99 | $71K | -28.1% | — |
| Nov 13SEC | Henry L. CharltonEvp & Chief Commercial And Mkt | Sell Plan | 4,7313,056 held (−61%) | $580.00 | $2.7M | -29.5% | — |
| Nov 13SEC | Henry L. CharltonEvp & Chief Commercial And Mkt | Sell Plan | 2,9017,787 held (−27%) | $580.00 | $1.7M | -29.5% | — |
| Nov 13SEC | Henry L. CharltonEvp & Chief Commercial And Mkt | Sell Plan | 2,8987,787 held (−27%) | $580.00 | $1.7M | -29.5% | — |
| Nov 13SEC | Henry L. CharltonEvp & Chief Commercial And Mkt | Sell Plan | 2,5657,787 held (−25%) | $580.00 | $1.5M | -29.5% | — |
| Nov 13SEC | Craig H. BarrattDirector | Sell Plan | 750 | $580.00 | $435K | -29.5% | — |
| Nov 13SEC | Henry L. CharltonEvp & Chief Commercial And Mkt | Sell Plan | 6367,787 held (−8%) | $580.00 | $369K | -29.5% | — |
| Nov 12SEC | Brian Edward MillerEvp & Chief Digital Officer | Sell Plan | 2,2025,758 held (−28%) | $575.00 | $1.3M | -28.9% | — |
| Nov 12SEC | Brian Edward MillerEvp & Chief Digital Officer | Sell Plan | 1,2985,758 held (−18%) | $575.00 | $746K | -28.9% | — |
| Nov 12SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 105 | $560.00 | $59K | -27.0% | — |
| Nov 6SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 1,908473 held (−80%) | $550.00 | $1.0M | -25.6% | — |
| Nov 6SEC | Fredrik WidmanVp Corporate Controller | Sell Plan | 159473 held (−25%) | $550.00 | $87K | -25.6% | — |
| Oct 29SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 5,030353 held (−93%) | $548.43 | $2.8M | -25.4% | — |
| Oct 29SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 1,379353 held (−80%) | $548.43 | $756K | -25.4% | — |
| Oct 29SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 1,153353 held (−77%) | $548.43 | $632K | -25.4% | — |
| Oct 29SEC | Myriam CuretEvp & Chief Medical Officer | Sell Plan | 125 | $543.00 | $68K | -24.7% | — |
| Oct 27SEC | Gary S. GuthartChair | Sell Plan | 28,80027,027 held (−52%) | $547.56 | $15.8M | -25.3% | — |
| Oct 27SEC | David J. RosaCEO | Sell Plan | 24,500234,256 held (−9%) | $547.55 | $13.4M | -25.3% | — |
| Oct 27SEC | Craig H. BarrattDirector | Sell Plan | 2,193 | $548.01 | $1.2M | -25.4% | — |
| Oct 27SEC | Gary S. GuthartChair | Sell Plan | 1,40017,120 held (−8%) | $546.35 | $765K | -25.1% | — |
| Oct 27SEC | Gary S. GuthartChair | Sell Plan | 1,40017,120 held (−8%) | $546.18 | $765K | -25.1% | — |
Similar past setups: not applicable. ISRG has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with ISRG in the Research Lab
ISRG has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Intuitive Surgical insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $65.4M of ISRG stock on the open market; P/E 53.0 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
ISRG insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $19.8M | 16 |
| Q3 2026 | — | 0 | $5.0M | 20 |
| Q2 2026 | — | 0 | $3.1M | 15 |
| Q1 2026 | — | 0 | $21.3M | 21 |
| Q4 2025 | — | 0 | $64.0M | 27 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Intuitive Surgical insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $65.4M. 99 of 99 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ISRG earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 20, 2026 | +10.5% | None | -1.2%S&P +0.9% | pending |
| Jul 16, 2026 | -2.2% | None | -11.2%S&P -1.5% | +14.2% |
| Apr 21, 2026 | +3.0% | None | +3.9%S&P +0.4% | -9.4% |
| Jan 22, 2026 | -11.7% | None | +0.1%S&P +0.6% | -3.8% |
| Jan 14, 2026 | -2.4% | Sold $509K | -3.6%S&P -0.2% | -10.3% |
| Oct 21, 2025 | +1.4% | None | +15.0%S&P -0.5% | +6.6% |
| Jul 22, 2025 | -5.2% | None | -2.7%S&P +0.9% | -5.1% |
| Apr 22, 2025 | +3.7% | None | +4.2%S&P +4.2% | +10.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ISRG short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded ISRG
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | -9.6% |
| Markwayne MullinSenate | Bought $15,001 - $50,000 | Dec 29, 2025 | Jan 16, 2026 | -28.9% |
| Markwayne MullinSenate | Bought $50,001 - $100,000 | Sep 24, 2025 | Oct 1, 2025 | -7.9% |
Insiders at Intuitive Surgical
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Gary S. GuthartDirector | — | $62.4M | Nov 5, 2026 | — | — |
| David J. RosaCEO | — | $13.4M | Jul 13, 2026 | — | — |
| Myriam CuretEvp & Chief Medical Officer | — | $8.4M | Mar 11, 2026 | — | — |
| Henry L. CharltonEvp & Chief Commercial And Mkt | — | $8.0M | Mar 2, 2026 | — | — |
| Mark BrosiusEvp & Chief Mfg And Supply Cha | — | $6.1M | Nov 18, 2026 | — | — |
| Fredrik WidmanVp Corporate Controller | — | $6.0M | Nov 2, 2026 | — | — |
| Craig H. BarrattDirector | — | $2.7M | Nov 5, 2026 | — | — |
| Iman JeddiSvp & Gm Da Vinci Platforms & | — | $2.4M | Jun 2, 2026 | — | — |
| Brian Edward MillerEvp & Chief Digital Officer | — | $2.0M | Nov 12, 2025 | — | — |
| Gary LoebGeneral Counsel | — | $683K | Nov 12, 2026 | — | — |
| Patricia L. WadorsSvp Chief Human Resources Offi | — | $588K | Oct 26, 2026 | — | — |
| Amy L. LaddDirector | — | $472K | Aug 11, 2026 | — | — |
| Jami K. NachtsheimDirector | — | — | Apr 30, 2026 | 1 of 1 | — |
| Lewis ChewDirector | — | — | Apr 30, 2026 | — | — |
| Joseph C. BeeryDirector | — | — | Apr 30, 2026 | — | — |
| Amal M. JohnsonDirector | — | — | Apr 30, 2026 | 1 of 1 | — |
| Keith R. LeonardDirector | — | — | Apr 30, 2026 | — | — |
| Sreelakshmi KolliDirector | — | — | Apr 30, 2026 | — | — |
| Monica P. ReedDirector | — | — | Apr 30, 2026 | — | — |
| Jamie SamathCFO | — | — | Mar 2, 2026 | — | — |
Board links: companies that share insiders with ISRG
Directors and executives who filed Form 4s for ISRG and another company in the last 12 months.
- ANETArista Networks Lewis Chew Director here · Director at ANET · latest filing Nov 17, 2026
- ARQTArcutis Biotherapeutics Keith R. Leonard Director here · Director at ARQT · latest filing Apr 30, 2026
- CDNSCadence Design Systems Lewis Chew Director here · Director at CDNS · latest filing Nov 12, 2026
- ESSEssex Property Trust Amal M. Johnson Director here · Director at ESS · latest filing May 14, 2026
- INSPInspire Medical Systems Myriam Curet Evp & Chief Medical Officer here · Director at INSP · latest filing Mar 11, 2026
- INTCIntel Craig H. Barratt Director here · Director at INTC · latest filing Nov 5, 2026
- KLACKLA Jamie Samath CFO here · Director at KLAC · latest filing Nov 5, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ISRG stock: common questions
Are Intuitive Surgical insiders buying ISRG stock?
No. No Intuitive Surgical insider reported an open-market purchase of ISRG in the past 12 months.
Are Intuitive Surgical insiders selling ISRG stock?
9 insiders reported sales worth $65.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ISRG's P/E ratio?
ISRG trades at about 53.0 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is ISRG's 52-week range?
Over the past year ISRG has traded between $332.02 and $592.85. It last closed at $409.00 on Nov 19, 2026.